Osteoporosis - primary prevention

Whether or not a postmenopausal woman with osteoporosis is offered one of these drugs to prevent bone fractures will depend on her age, her bone density and how many risk factors for fracture and indicators of fragile bones she has. In principle, alendronate is recommended as a possible treatment f ...

Read the complete summary

Whether or not a postmenopausal woman with osteoporosis is offered one of these drugs to prevent bone fractures will depend on her age, her bone density and how many risk factors for fracture and indicators of fragile bones she has.

In principle, alendronate is recommended as a possible treatment for preventing bone fractures in postmenopausal women who have had osteoporosis diagnosed but have not had a fracture.

If a woman can't take alendronate, risedronate and etidronate are recommended under certain circumstances as possible alternative treatments to prevent fractures.

If a woman can't take alendronate or either risedronate or etidronate, then strontium ranelate is recommended under certain circumstances as a possible alternative treatment to prevent fractures.

Raloxifene is not recommended as a treatment for preventing fractures in postmenopausal women with osteoporosis who have not had a fracture.

The guidance says that women who are 75 or over may not need a bone scan to diagnose their osteoporosis.

The full versions of the final NICE guidance on the use of drugs for primary and secondary prevention of osteoporotic fractures have been available on the NICE website since 27 October.

The hard copies of the guidance will be produced in accordance with our monthly publication schedule, on 26 November.  The NHS funding directive will come into effect once the hard copy has been issued to the NHS.

hide